Biocon Investment Analyzed

Key Points

• Nuvama Equities recommends ‘Buy’ for Biocon, target price ₹480.
• Biocon is boosting its stake in Biocon Biologics (BBL) strategically.
• A $500 million share buyback will fund part of the BBL acquisition.
• Consolidation eliminates discounts, simplifying operations and boosting profits.
• Stronger biosimilars (Stelara) and new contracts drive potential recovery.
• Improved debt levels will positively impact Biocon’s financial health.

Biocon Investment Analysis

Nuvama Institutional Equities remains confident in Biocon, maintaining a “Buy” rating and a target price of ₹480. This recommendation is based on several key developments within the company, particularly its strategic move to increase its ownership in Biocon Biologics (BBL). The company plans to purchase the remaining 23.3% stake, which is a central part of its strategy to consolidate its biologics arm.

This acquisition is a significant step, along with planned cost savings. Biocon will pay out around $400 million in cash to Viatris, while also exchanging shares – a 773 million dollar deal – with Viatris and other investors. This combined effort will give Biocon full control of Biologics and allow it to streamline its operations.

The analysts believe this move will unlock value for investors by eliminating a “holding-company discount,” meaning the way the Biologics business was previously valued is no longer a factor. Additionally, they anticipate operational improvements through shared resources across areas like manufacturing and supply chains. While full benefits might take time, Biocon expects synergies to drive stronger profits.

To fund the acquisition, Biocon intends to conduct a share buyback (also known as a Qualified Institutional Placement or QIP) of up to $500 million. This will involve issuing new shares to raise capital. The share swap will distribute around 280 million incremental Biocon shares, representing roughly 17% dilution at a price of ₹405 per share.

Biocon anticipates that its stronger biosimilars, such as Stelara (with a 15% market share), and other products like bAspart and denosumab, will be key drivers of growth. New product launches and increased business contracts – particularly in the CRDMO (Contract Research and Development Manufacturing Organization) sector – will further boost the company’s performance. These factors combined will support a recovery starting in FY27.

Furthermore, Biocon is focusing on reducing its debt, aiming to decrease its debt-to-EBITDA ratio from 4.5 times (as of FY23) to a more manageable 2.5 times. This improved financial situation, combined with the projected recovery, should positively impact Biocon’s overall performance and attract investors.

“With the swap ratio valuing BBL at 5.5 billion dollars, the combined transaction including the QIP could lead to around 280 million incremental Biocon shares. This may introduce excess liquidity in the near term with a six-month lock-in, but Biocon will capture 100 per cent of BBL’s economics. Our preliminary estimates suggest no major changes in EPS or SoTP, while synergies, if unlocked, could drive accretion,” the brokerage said.

Biocon’s strategic investment and focus on core growth areas promise a strong future for the company.